{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:28:33Z","timestamp":1786699713925,"version":"build-2736575974"},"reference-count":40,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Consortium of Multiple Sclerosis Centers"},{"name":"Department of Defense through the Multiple Sclerosis Research Program","award":["W81XWH-21-1-0721"],"award-info":[{"award-number":["W81XWH-21-1-0721"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,5,4]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Associations between comorbidity and reduced persistence to disease-modifying therapies (DMTs) in multiple sclerosis (MS) have been identified. Limited information is available regarding the association of comorbidity with safety outcomes. The study objective was to evaluate the association of comorbidities with safety outcomes and persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a two-stage meta-analysis of individual participant data from phase III clinical trials of MS DMTs. Individual comorbidities and comorbidity burden, defined as the sum of all comorbidities (n=15), were examined. Safety outcomes, defined using adverse event (AE) data, were reviewed to identify specific AEs of interest, including infection; treatment-emergent autoimmune disease; cancer; elevated transaminases and lymphopenia. We also examined any early trial discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 17 clinical trials representing 16\u2009794\u2009MS participants. Over a 2-year follow-up, the pooled proportion of AEs was 64% (95% CI 59.4% to 68.9%) and the majority were infection AEs. Increasing comorbidity burden was associated with an increased rate of AEs (rate ratio (95% CI) 1: 1.13 (1.09 to 1.17); 2: 1.19 (1.14 to 1.23); \u22653: 1.25 (1.18 to 1.33)) compared with those with no comorbidity. When pooled across trials, early discontinuation affected 17% of participants (95% CI 13.8% to 20.9%). A higher risk of trial discontinuation was associated with higher comorbidity burden (2: 1.23 (1.07 to 1.42); \u22653: 1.19 (1.01 to 1.40)) compared with those with no comorbidity. Psychiatric disorders were associated with trial discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher comorbidity burden is associated with increased risk of experiencing safety outcomes and early DMT discontinuation among individuals with MS enrolled in clinical trials of MS-DMTs, highlighting the important role of comorbidities in the safety and persistence of DMTs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2024-335710","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T21:30:22Z","timestamp":1748122222000},"page":"1070-1076","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis"],"prefix":"10.1136","volume":"96","clinical-trial-number":[{"clinical-trial-number":"nct00027300","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00030966","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00211887","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00289978","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00355134","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00213135","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00340834","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00530348","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00548405","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00451451","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00420212","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00906399","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00731692","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01247324","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01412333","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01194570","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01416181","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02792218","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02792231","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00027300","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00030966","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00211887","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00289978","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00355134","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00213135","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00340834","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00530348","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00548405","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00451451","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00420212","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00906399","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00731692","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01247324","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01412333","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01194570","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01416181","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02792218","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02792231","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00340834","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00906399","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00211887","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1088-110X","authenticated-orcid":false,"given":"Amber","family":"Salter","sequence":"first","affiliation":[{"name":"Section on Statistical Planning and Analysis, Neurology, UT Southwestern, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Lancia","sequence":"additional","affiliation":[{"name":"Section on Statistical Planning and Analysis, Neurology, UT Southwestern, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaarina","family":"Kowalec","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Manitoba Faculty of Health Sciences, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Epidemiology & Biostatistics, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-0322","authenticated-orcid":false,"given":"Kathryn","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1855-5595","authenticated-orcid":false,"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada"},{"name":"Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"2026081401350740000_96.11.1070.1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208006","article-title":"Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study","volume":"102","author":"Ng","year":"2024","journal-title":"Neurology (ECronicon)"},{"key":"2026081401350740000_96.11.1070.2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27012"},{"key":"2026081401350740000_96.11.1070.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2011.01532.x"},{"key":"2026081401350740000_96.11.1070.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02146.x"},{"key":"2026081401350740000_96.11.1070.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318248deea"},{"key":"2026081401350740000_96.11.1070.6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004686"},{"key":"2026081401350740000_96.11.1070.7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002471"},{"key":"2026081401350740000_96.11.1070.8","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209135","article-title":"Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations","volume":"102","author":"Salter","year":"2024","journal-title":"Neurology (ECronicon)"},{"key":"2026081401350740000_96.11.1070.9","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw075"},{"key":"2026081401350740000_96.11.1070.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"2026081401350740000_96.11.1070.11","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaneurol.2024.2920","article-title":"Comorbidity and Disease Activity in Multiple Sclerosis","volume":"81","author":"Salter","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026081401350740000_96.11.1070.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"2026081401350740000_96.11.1070.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70049-3"},{"key":"2026081401350740000_96.11.1070.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01314-8"},{"key":"2026081401350740000_96.11.1070.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30069-3"},{"key":"2026081401350740000_96.11.1070.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"2026081401350740000_96.11.1070.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106009"},{"key":"2026081401350740000_96.11.1070.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"2026081401350740000_96.11.1070.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396"},{"key":"2026081401350740000_96.11.1070.20","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23863"},{"key":"2026081401350740000_96.11.1070.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"2026081401350740000_96.11.1070.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3"},{"key":"2026081401350740000_96.11.1070.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"2026081401350740000_96.11.1070.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206328"},{"key":"2026081401350740000_96.11.1070.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114287"},{"key":"2026081401350740000_96.11.1070.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"2026081401350740000_96.11.1070.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"2026081401350740000_96.11.1070.28","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516681198"},{"key":"2026081401350740000_96.11.1070.29","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12130"},{"key":"2026081401350740000_96.11.1070.30","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200164","article-title":"Multiple Sclerosis, Disease-Modifying Therapies, and Infections","volume":"10","author":"Langer-Gould","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026081401350740000_96.11.1070.31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026081401350740000_96.11.1070.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.06.036"},{"key":"2026081401350740000_96.11.1070.33","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3168w"},{"key":"2026081401350740000_96.11.1070.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.09.009"},{"key":"2026081401350740000_96.11.1070.35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002543"},{"key":"2026081401350740000_96.11.1070.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.05.006"},{"key":"2026081401350740000_96.11.1070.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103249"},{"key":"2026081401350740000_96.11.1070.38","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211031128"},{"key":"2026081401350740000_96.11.1070.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.09.008"},{"key":"2026081401350740000_96.11.1070.40","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14608"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-335710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:35:21Z","timestamp":1786696521000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-335710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jnnp-2024-335710"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-335710","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]}}}